Prosecution Insights
Last updated: July 17, 2026
Application No. 18/702,220

A METHOD FOR THE PREPARATION OF INDOLE-3-CARBOXYLIC ACID DERIVATIVES

Non-Final OA §102
Filed
Apr 17, 2024
Priority
Oct 20, 2021 — IN 202111047806 +1 more
Examiner
SCHMITT, MICHAEL J
Art Unit
Tech Center
Assignee
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
OA Round
1 (Non-Final)
57%
Grant Probability
Moderate
1-2
OA Rounds
7m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
366 granted / 647 resolved
-3.4% vs TC avg
Strong +22% interview lift
Without
With
+21.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
37 currently pending
Career history
684
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
46.8%
+6.8% vs TC avg
§102
11.1%
-28.9% vs TC avg
§112
3.5%
-36.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 647 resolved cases

Office Action

§102
DETAILED ACTION Claims 1-7 are pending. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application, filed 4/17/2024 is a National Stage entry of PCT/IN2022/050940, International Filing Date of 10/20/2022 and claims foreign priority to 202111047806, filed 10/20/2021. Claim Objections Claims 5, 6, and 7 are objected to because of the following informalities: the claims refer to compounds that are drawn in the Specification, Applicant should have the compound structure in the claims. Appropriate correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 3 and 4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry Entry 1118854-34-4 entered into the database on 3/11/2009. Claims 3 and 4 are directed to the following compound: PNG media_image1.png 106 156 media_image1.png Greyscale The CAS Registry teaches: PNG media_image2.png 318 666 media_image2.png Greyscale Claims 3 and 4 are anticipated. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 3 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Corbett US 2004/0067939 A1 published 4/8/2004. Claim 3 is directed to a genus of compounds defined by Formula A: PNG media_image3.png 306 452 media_image3.png Greyscale In this genus the R1 group includes halogen, the R2 group includes hydrogen, the X and Y are defined as the Figure shows. Corbett teaches the following genus: PNG media_image4.png 148 196 media_image4.png Greyscale Corbett specifically teaches the following compound: PNG media_image5.png 138 240 media_image5.png Greyscale This compound anticipates claim 3 of the instant application. Allowable Subject Matter Claims 1-2 are allowed. Claims 5-7 are objected to for having minor informalities, but would be allowable if rewritten to introduce the structure of the compounds being referred to in the Specification. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL J SCHMITT whose telephone number is (571)270-7047. The examiner can normally be reached M-F 8-6 MidDay Flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL J SCHMITT/ Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/ Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Apr 17, 2024
Application Filed
Jul 02, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673037
METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS
3y 9m to grant Granted Jul 07, 2026
Patent 12667620
ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
1y 2m to grant Granted Jun 30, 2026
Patent 12662488
SPIROCYCLIC COMPOUNDS
3y 3m to grant Granted Jun 23, 2026
Patent 12648959
AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF
3y 9m to grant Granted Jun 09, 2026
Patent 12642791
Inhibitors of Lysyl Oxidases
2y 11m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
57%
Grant Probability
78%
With Interview (+21.7%)
2y 10m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 647 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month